Nikolaos Trikalinos, MD

Medical Oncologist

Nikolaos Trikalinos

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Nikolaos Trikalinos, MD

Watch video on YouTube

Nikolaos Trikalinos, MD

2 mins

Washington University medical oncologist Nikolaos Trikalinos, MD, discusses what gastrointestinal and neuroendocrine cancer patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Trikalinos: https://siteman.wustl.edu/doctor/nikolaos-trikalinos/

Learn more about the Siteman Approach to Stomach Cancer: https://siteman.wustl.edu/treatment/cancer-types/stomach/our-approach/

Discover treatment options for gastrointestinal neuroendocrine tumors (GI NETs): https://siteman.wustl.edu/treatment/cancer-types/stomach/gi-net-treatments/

Clinical Expertise

Primary Academic Title

Associate Professor of Medicine, Department of Internal Medicine, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2010: American Board of Internal Medicine
  • 2014: American Board of Internal Medicine, Hematology
  • 2014: American Board of Internal Medicine, Oncology

Training

  • 2005 - 2007 : Research Associate, Epidemiology, University of Ioannina Medical School, Ioannina, Greece
  • 2007 - 2010: Resident, Internal Medicine, MetroWest Medical Center, Framingham, MA
  • 2010 - 2011: Chief Resident, Internal Medicine, MetroWest Medical Center, Framingham, MA
  • 2011 - 2014: Fellow, Hematology and Oncology, Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD

Education

  • 2005: MD, University of Ioannina Medical School, Ioannia, Greece

Research & Selected Publications

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Authors:

Le DT, Folprecht G, Varghese AM, one or more additional authors omitted Trikalinos NA, one or more additional authors omitted Lenz HJ

Journal & Year:

J Immunother Cancer | 2026

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Authors:

Chan JA, Geyer S, Zemla T, one or more additional authors omitted Trikalinos NA, one or more additional authors omitted Meyerhardt JA

Journal & Year:

N Engl J Med | 2025

Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid
Authors:

Schutte J, Mardani M, Weilbaecher K, one or more additional authors omitted Trikalinos NA

Journal & Year:

BMJ Case Rep | 2024

Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm
Authors:

Trikalinos NA, Kim H, Vijayan A, Amurao M , Prasad V

Journal & Year:

J Neuroendocrinol | 2024

A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Authors:

Grierson PM, Suresh R, Tan B, one or more additional authors omitted Trikalinos NA, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res | 2023

Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations
Authors:

Navale P, Chatterjee D, Itani M, Trikalinos NA

Journal & Year:

Virchows Arch | 2023